Element Science Expands Executive Leadership Team to Accelerate Commercial Growth and Execution

Key leadership hires bring deep medtech scaling expertise to advance the Jewel Patch Wearable Cardioverter Defibrillator

SAN FRANCISCO--(BUSINESS WIRE)--Element Science, a pioneering health technology company and creator of the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) to monitor and protect patients at high-risk of sudden cardiac arrest (SCA), today announced several strategic appointments to its executive leadership team. These key hires bring extensive industry experience across commercial strategy, operations, finance, and human resources to drive the company's next phase of growth.

"Element Science is entering an exciting new phase as we build the organization to support the commercialization of the Jewel Patch, and position the company for its next stage of growth," said Doug Devine, Chief Executive Officer of Element Science. "These appointments reflect our continued investment in building a world-class leadership team with the expertise needed to execute our strategy. Paul, Mark, Eric and Cheeka each bring proven track records from some of the medtech industry’s most successful companies. Together they bring decades of experience scaling innovative companies, and will strengthen our ability to execute, innovate and expand access to Jewel, while advancing our mission to redefine care for patients at risk of sudden cardiac arrest.”

Executive Appointments

• Paul Mandina, Chief Revenue Officer
  Paul brings more than 20 years of medtech commercial leadership experience. Most recently, he served as VP of U.S. Sales at Medtronic, where he led a $500 million portfolio to double-digit growth. Having previously built and scaled teams at Nevro, St. Jude Medical, and Intuitive Surgical, Mandina will shape Element Science's commercial strategy and build capabilities for market expansion.

• Mark Hughes, Chief Operating Officer
  Mark joins Element Science from iRhythm, where he spearheaded operations through major commercial scaling. He brings deep manufacturing and supply chain expertise essential to guiding Element Science into early U.S. commercialization.

• Eric Samuels, Chief Financial Officer
  Eric assumes the CFO role with extensive financial and operational experience from previous leadership roles at iRhythm and Intel. He will oversee the expansion of Element Science's financial and operational foundation to support long-term corporate growth.

• Cheeka Trikha, Head of People and Organization
  Cheeka joins from Cognite, where she led People Business Partnering, following senior HR leadership roles at SAP, iRhythm, Confluent and Cognite. She brings a strong blend of medtech experience and organizational scaling expertise as Element Science continues to grow its talent base.

This is an exciting time at Element Science. Following our recognition by Fast Company as one of the World’s Most Innovative Companies of 2026, we’re continuing to build the team and capabilities to advance our mission and shape the future of cardiac care.

About Element Science, Inc.

Element Science, Inc. is a medical device and digital health company focused on developing solutions at the intersection of clinical-grade wearables, machine learning algorithms, and lifesaving¹ therapies that address leading causes of death and hospitalization in patients with heart disease, primarily as they transition from the hospital-to-home. By putting the needs of patients and physicians first, our personalized digital devices, which are designed for function, comfort, and ease-of-use, aim to redefine the paradigm of care for these patients. Our first product, the Jewel Patch Wearable Cardioverter Defibrillator, is initially targeted at treating more than 850,000 patients in the U.S. and Europe with an elevated temporary risk of potentially experiencing a lethal heart rhythm. Based in San Francisco, our investors include Third Rock Ventures, Google Ventures, Deerfield Management, Qiming Venture Partners USA, Cormorant Asset Management, Boston Scientific and Invus Opportunities.

Important Safety Information

The Jewel Patch Wearable Cardioverter Defibrillator is a prescription device. The Jewel Patch Wearable Cardioverter Defibrillator is indicated for patients 18 years of age and older who are at risk for sudden cardiac arrest and are not candidates for or refuse an implantable defibrillator. For complete indications, contraindications, warnings, precautions and adverse events, see https://elementscience.com/manuals/.

To learn more, visit www.elementscience.com.

¹Hummel, J. etc al, Jewel IDE Study, JACC, 2024 Aug, 84(6) 525-536